Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TECH 
Bio-Techne Corp (TECH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: TECH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $67.42
1 Year Target Price $67.42
| 7 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.62% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.33B USD | Price to earnings Ratio 130.3 | 1Y Target Price 67.42 |
Price to earnings Ratio 130.3 | 1Y Target Price 67.42 | ||
Volume (30-day avg) 15 | Beta 1.47 | 52 Weeks Range 45.87 - 78.94 | Updated Date 11/5/2025 |
52 Weeks Range 45.87 - 78.94 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When Before Market | Estimate 0.43 | Actual 0.42 |
Profitability
Profit Margin 6.02% | Operating Margin (TTM) 36.3% |
Management Effectiveness
Return on Assets (TTM) 6.3% | Return on Equity (TTM) 3.68% |
Valuation
Trailing PE 130.3 | Forward PE 30.4 | Enterprise Value 9948877751 | Price to Sales(TTM) 7.65 |
Enterprise Value 9948877751 | Price to Sales(TTM) 7.65 | ||
Enterprise Value to Revenue 8.16 | Enterprise Value to EBITDA 45.87 | Shares Outstanding 155693441 | Shares Floating 153707880 |
Shares Outstanding 155693441 | Shares Floating 153707880 | ||
Percent Insiders 0.27 | Percent Institutions 103.29 |
Upturn AI SWOT
Bio-Techne Corp
Company Overview
History and Background
Bio-Techne Corp was founded in 1981. Initially known as R&D Systems, the company has grown through strategic acquisitions and organic growth to become a global leader in biotechnology. Key milestones include expanding product offerings, international expansion, and acquisitions of companies like Tocris Bioscience and Exosome Diagnostics.
Core Business Areas
- Protein Sciences Segment: Develops, manufactures, and sells biological reagents, including cytokines, growth factors, antibodies, and ELISA kits, used in research and diagnostics.
- Diagnostics and Genomics Segment: Offers molecular diagnostic controls, clinical chemistry controls, and instruments for cell and gene therapy, genomics, and hematology.
- Spatial Biology Segment: Offers instruments and reagents for spatial multi-omics and high-plex spatial transcriptomics.
Leadership and Structure
Charles Kummeth serves as the President and CEO. The organizational structure includes various divisions focused on specific product lines and geographic regions, with a hierarchical reporting structure.
Top Products and Market Share
Key Offerings
- Cytokines and Growth Factors: Used in cell culture and research applications. Market share is estimated to be significant (approximately 20-25% in certain applications). Competitors include Thermo Fisher Scientific (TMO), Merck KGaA (MRK), and Danaher (DHR).
- ELISA Kits: Enzyme-linked immunosorbent assays for detecting and quantifying substances. Competitors are Thermo Fisher Scientific (TMO), Abcam (ABC), and Qiagen (QGEN).
- Exosome Diagnostics: Liquid biopsy platform for cancer diagnostics. Competitors are Guardant Health (GH), Exact Sciences (EXAS), and Illumina (ILMN).
- Advanced Cell Diagnostics (ACD): RNA in situ hybridization technology. Estimated market share to be around 15-20%. Key competitors are NanoString Technologies (NSTG), Akoya Biosciences (AKYA), and Roche (ROG).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by rapid innovation, increasing demand for research tools and diagnostics, and stringent regulatory requirements. Growth is driven by advancements in genomics, proteomics, and personalized medicine.
Positioning
Bio-Techne Corp is a leading player in the life sciences and diagnostics markets, with a strong reputation for quality and innovation. Its competitive advantages include a broad product portfolio, established distribution channels, and a focus on customer service.
Total Addressable Market (TAM)
The total addressable market is estimated at $50+ billion, encompassing research reagents, diagnostics, and cell and gene therapy tools. Bio-Techne is well-positioned to capture a significant portion of this TAM through organic growth and acquisitions.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Strong brand reputation
- Established distribution network
- Recurring revenue streams
- Experienced management team
Weaknesses
- High operating costs
- Reliance on third-party suppliers
- Integration challenges with acquisitions
- Sensitivity to economic downturns
Opportunities
- Expanding into emerging markets
- Developing new diagnostic tests
- Acquiring complementary businesses
- Leveraging digital technologies
- Growth in cell and gene therapy markets
Threats
- Increased competition
- Regulatory changes
- Technological obsolescence
- Economic recession
- Intellectual property infringement
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ILMN
Competitive Landscape
Bio-Techne competes with larger diversified companies. It differentiates itself through specialized products and customer service.
Major Acquisitions
Asuragen
- Year: 2019
- Acquisition Price (USD millions): 257
- Strategic Rationale: Expanded molecular diagnostics offerings.
Quad Technologies
- Year: 2020
- Acquisition Price (USD millions): 17
- Strategic Rationale: Cell separation technology added to cell and gene therapy business.
Growth Trajectory and Initiatives
Historical Growth: Bio-Techne has experienced strong growth through organic expansion and strategic acquisitions.
Future Projections: Analysts expect continued growth in revenue and earnings, driven by demand for research tools and diagnostics. Revenue growth is expected to be around 5-10% annually over the next few years.
Recent Initiatives: Recent initiatives include expanding into new geographic markets, developing new diagnostic tests, and acquiring companies in complementary businesses.
Summary
Bio-Techne is a strong company with a diverse product portfolio, demonstrating consistent revenue growth. Its strategic acquisitions strengthen its position in key markets. However, it faces challenges related to operating expenses and competition and thus must also look at the effect that changes in technology and innovation can have on revenue.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Research Reports
- Company Investor Relations
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bio-Techne Corp
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 1989-02-09 | CEO, President & Director Mr. Kim Kelderman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3100 | Website https://www.bio-techne.com |
Full time employees 3100 | Website https://www.bio-techne.com | ||
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.